A B S T R A C T To evaluate the possible role of microtubules in the cellular action of vasopressin on the mammalian kidney, the effects of microtubule-disrupting agents were studied in vivo and in vitro.
INTRODUCTION
The mechanism by which vasopressin regulates water permeability of certain epithelial membranes is only partially known. Considerable evidence accumulated in recent years indicates that cyclic AMP serves as an intracellular mediator in the cellular action of vasopressin (1, 2) . The mechanism by which cyclic AMP formed under the influence of vasopressin increases water permeability of collecting ducts remains unknown. Still hypothetical is the idea that cyclic AMP acts on the lumenal plasma membrane through its influence on protein phosphorylation (3) (4) (5) . Taylor, Mamelak, Raven, and Maffly (6) found that some drugs known to disrupt the structure of microtubules partially inhibit the increase in water permeability in response to vasopressin and exogenous cyclic AMP in isolated toad urinary bladders. The stimulatory effect of vasopressin and cyclic AMP on active sodium transport in the same tissue was not influenced by these drugs. This suggests that microtubules are involved in the regulation of water permeability by vasopressin in steps subsequent to the cyclic AMP formation.
The regulatory effect of vasopressin on water permeability of the distal nephron in the mammalian kidney appears to be analogous to the amphibian urinary bladder system, including the mediatory role of cyclic AMP (1, 2) . The presence of microtubules in cells of collecting ducts has been described (7) .
In the present study, colchicine and vinblastine, two microtubule-disrupting agents (8) shown to elicit supramaximal antidiuretic effect in rats (9) . Lumicolchicine was prepared by irradiation of colchicine with a long wavelength ultraviolet lamp as described by Mizel and Wilson (10 (Tables I and III Additional experiments were conducted to test for nonspecific toxic effects of colchicine. A group of five rats was treated with colchicine, as described in Table I and compared with the same number of control animals. No difference was observed between control and colchicine-treated rats in levels of serum creatinine, blood urea nitrogen, calcium, potassium, sodium, or in urinary pH measured at the end of experiment. Kidneys were examined histologically and no pathological changes were observed in glomeruli, tubuli, or other renal structures. In another control experiment, animals were again treated with the colchicine as described in Table I and the drug was then discontinued for 3 days. After this rest period, the rats were injected with exogenous vasopressin. The animals treated previously with colchicine did not differ in the antidiuretic response from the control animals. Urine osmolality (Uo.m) ' Dosages of alkaloids utilized in the present study were based on estimation from other studies (13) and preliminary experiments. Dosages lower than those employed in present experiments produced no or only borderline effect.
In vitro methods. The content of microtubular protein was determined by utilizing its ability to bind colchicine specifically (8) . The colchicine-binding protein was assayed by the method described by Weisenberg, Borisy, and Taylor (14) with DEAE filter paper disks. When particulate fractions of renal medullary homogenate were studied and compared with soluble proteins, double-layer disks of DEAE cellulose paper and GF/C Whatman glass fiber papers were used to assure retention of membrane fragments. GF/C glass fiber paper itself retained neither [ Adenylate cyclase was assayed by the method described in our previous study (15) . For the chromatographic separation of cyclic AMP from other nucleotides, we used a modification described recently (16) .
'Abbreviations used in this paper: Cr, creatinine; GFR, glomerular filtration rate; Uom, urine osmolality; UV, total solute excretion. Rats from experimental group received 0.1 mg colchicine intraperitoneally on days 3, 4, 5, and 6; the control group received only solvent. On days 4, 5, and 6 both groups were administered 0.5 U of pitressin tannate in oil subcutaneously. Each group consisted of six rats. At the end of experiment serum creatinine levels in control and experimental group were 0.789±0.059 and 0.727±0.038 mg/100 ml±SEM, respectively. These values were not significantly different from each other (t test).
Cyclic AMP phosphodiesterase was assayed by the method described in another of our studies (17) . None of the tested drugs interfered with the breakdown of 5'-AMP to nucleosides and phosphate by snake venom 5'-nucleotidase.
For the assay of cyclic AMP-dependent protein kinase, we used the same method as in our earlier experiments (4) with the exception that the initial trichloroacetic acid (TCA) precipitate was dissolved in 0.1 ml of 1 N NaOH and reprecipitated by 5%7 TCA before the final washing on Millipore filters (Millipore Corp., Bedford, Mass.). All assays were run in triplicate.
In studies on subcellular localization of colchicine-binding protein, the fractions were prepared from bovine kidney medulla. All preparations were done at 0-2°C. The preparation of plasma membranes followed in principle the method described by Fitzpatrick, Davenport, Forte, and Landon (18) except for -the following modification: all solutions contained 10 mM MgCl2, 10 mM potassium phosphate, 2X 10-4 M GTP and 5 X 10-M EDTA, and were adjusted to pH 6.8. These conditions stabilize colchicine-binding protein (19) . Other subcellular fractions were prepared as follows: The pellet from the first centrifugation in the above-mentioned modified procedure was resuspended in 2 M sucrose, centrifuged at 13,000 g for 10 min, and the pellet was taken as the "nuclear" fraction. The supernate from the first centrifugation in the above-mentioned modified procedure for plasma membrane preparation was further centrifuged for 20 min at 10,000 g. The sediment was resuspended in homogenizing medium and recentrifuged as before. The resulting pellet represented the "mitochondrial" fraction. The supernate from the first centrifugation at 10,000 g for 20 min was further centrifuged at 100,000 g for 60 min and the supernate was taken as the "cytosol." The sediment was resuspended in homogenizing medium and centrifuged again at 100,000 g for 60 min and the pellet was then taken as the "microsomal" fraction. The fractions were quickly frozen in dry ice and kept in dry ice until assayed for colchicine-binding activity. Fractions for studies of adenylate cyclase, cyclic AMP phosphodiesterase, and protein kinase activities were prepared in a slightly different way. The plasma membrane fraction was prepared according to the method of Fitzpatrick et al. (18) as employed in our previous studies (4) . The supernate from the first centrifugation in this procedure was further centrifuged for 60 min at 100,000 g, and the supernate (cytosol) was used as a source of protein kinase and cyclic AMP phosphodiesterase activities. The protein content in preparations was determined by the method of Lowry, Rosebrough, Farr, and Randall (20) . Radioactivity was determined by liquid scintillation counting. Student's t test was used for statistical evaluation of results for both group and paired comparisons (21) .
RESULTS

In vivo studies
Effect of colchicine. The effect of colchicine was tested on 12 rats divided into two equal groups. The first 2 days were the control period, and on the 3rd day the experimental group received 0.1 mg of colchicine intraperitoneally divided into two daily doses. On the 4th, 5th, and 6th days the experimental group received the same dose of colchicine as on the 3rd day, and both control and experimental groups received 0.5 U of Pitressin subcutaneously. The administration of colchicine itself (day 3) did not produce any change in urine flow Uo.r, (Fig. 1 ) UVosm, sodium, potassium, or creatinine excretion ( Fig. 1 and Table I ). As expected, the control group responded to exogenous vasopressin by a marked increase in Uosm (Fig. 1 ) and a corresponding decrease in urine flow, which continued for 2 subsequent days. On the other hand, the same dose of vasopressin did not change Uosm (Fig. 1 ) and urine flow in animals treated with colchicine either on the 4th or on the following experimental days. Despite a striking difference in the response to exogenous vasopressin in water excretion parameters (Uosm and urine flow) there were no significant differences between control and experimental groups in UVosm or UVcr (Table I and Fig. 1 ). The serum concentration of creatinine, measured at the end of experiment, was not different between control and colchicine-treated groups (Table I) . With the exception of a slight increase in sodium excretion in experimental animals on day 4, there was no difference in UVNa between control and experimental animals. Colchicine does not increase potassium excretion. The apparent differ- Days FIGURE 1 Response of urine osmolality to vasopressin in control rats (0 O) and in rats treated with colchicine on 3-6 experimental days (0 ---0). Each group consisted of six animals. * value significantly different from controls at P < 0.05 or more (t test).
ences in UVK on days 4-6 between the two groups are due to a decrease in potassium excretion in controls rather than to any change in the experimental group.
The effect of lumicolchicine was tested in the same manner described for colchicine. This derivative, given at the same dosage as colchicine, (0.1 mg/day), had no blocking effect on the antidiuretic response to exogenous vasopressin in terms of an increase in U08m and a decrease in urine flow (Table II) .
Effect of vinbiastine. The effect of vinblastine was evaluated in an experiment like that for colchicine, as described above, except that only five rats were used per group. Vinblastine sulfate was administered intraperitoneally to rats in the experimental group on days 3, 4, 5, and 6 in a single daily dose of 0.08 mg. Results are summarized in Table III and Fig. 2 . Vasopressin on the 4th day produced only a very small decrease in urine flow and a slight increase in Uosm (Fig. 2) in animals on vinblastine, while controls developed marked antidiuresis. This increase in U08m (+ A317+55 mosmol±SE)
in experimental group was much less than in the control group (+ A1,057±200 mosmol+SE) and difference between magnitude of the responses in these two groups was significant at P < 0.025. Moreover, on the following days (5th and 6th), while still receiving the same dose of vasopressin, the Uo0m in the experimental group dropped (Fig. 2) , urine flow (Table III) increased, and the difference in these parameters between control and experimental group increased further. There were no significant differences between the two groups in UVoum or in serum creatinine measured at the end of experiment (Table III) I Uo. increased in response to vasopressin from day 3 to day 4 in both control and experimental groups (A 888±108 and A 1,028±74 mosmol/kg H20, respectively). The increases in both groups were significant (P < 0.001) but not significantly different from each other. Rats from experimental group received 0.1 mg of lumicolchicine on days 3, 4, 5, and 6; control group received only solvent. On days 4, 5, and 6 both groups received 0.5 U of Pitressin tannate in oil subcutaneously. Number of animals in each group was six. There were no significant differences in urine flow or Uo.m between groups in any experimental day.
cretion of either sodium or potassium. The apparent differences in UVNa and UVK on days 4-6 are due to decreased excretion of sodium and potassium in controls rather than an increased excretion in experimental animals.
In vitro studies
Cyclic AMP metabolism. The effects of vinblastine and colchicine on the plasma membrane adenylate cyclase and cytosolic cyclic AMP phosphodiesterase were Basal or vasopressin-stimulated adenylate cyclase activity was not inhibited by colchicine or vinblastine (Table IV) . Since, as shown below, binding of colchicine to proteins is a rather slow process (Fig. 3) , the cytosol was incubated with either colchicine or vinblastine for 60 min before the assay for cyclic AMP phosphodiesterase. No change in cyclic AMP phosphodiesterase activity was observed due to preincubation with these two drugs (Table IV) for the control group. § UVc, value for control group was 5.06±0.37.
Rats in experimental groups received 0.08 mg vinblastine intraperitoneally on days 3-6; controls received only solvent. On days 4-6 both control and experimental were injected with 0.5 U of pitressin tannate in oil subcutaneously. Each group consisted of five rats. At the end of experiment, serum creatinine levels in control and experimental animals were 1.118±0.110 and 1.124 ±0.041 mg/100 ml, ±SEM. These values were not significantly different from each other (t-test).
phosphodiesterase) were studied ( (Fig.  4) . If the colchicine-binding activity of cytosol is taken as 100%, the ability of particulate fractions to bind
[PH]colchicine was less than 6%, plasma membranes being the least active. Colchicine-binding protein in renal medullary cytosol showed some characteristic properties described for analogous protein from brain (19) : the colchicine-binding activity was labile after prolonged incubation of 00C or after short incubation at 60'C, and (3) 4.98±0.33 (3) 4.86±0.12 (3) 38.4±0.56 (3) 42.434±2.26 (3) 39.1 1 ±2.35 (3) Cyclic AMP phosphodiesterase after preincubationj with colchicine or vinblastine nmol/min per mg protein* control 1.61±0.11 (6) Preincubated with colchicine 1.62±i0.11 (6) Preincubated with vinblastine 1.58±0.16 (6) * Mean±SE; number of experiments in parentheses. colchicine-binding protein was completely precipitated from the cytosol by incubation with vinblastine (Table  VI) .
DISCUSSION
In our in vivo experiments, two structurally unrelated microtubule-disrupting agents (8) prevented or markedly inhibited the antidiuretic action (decrease in urine volume and increase in Uo.m) of exogenous vasopressin. Lumicolchicine, a derivative of colchicine that does not interact with microtubules (22) , did not block the antidiuretic response to exogenous vasopressin.
Action of any drug which inhibits the antidiuretic action of vasopressin could be attributed to at least two different mechanisms: (a) interference with the action of vasopressin on cells of distal nephron to increase water permeability and (b) washout of the corticomedullary gradient of solutes. Although our results cannot decide completely between these two possibilities, several features favor the interpretation that colchicine and vinblastine interfered with the cellular action of vasopressin and not primarily by producing medullary solute washout. Since no changes in UVoum occurred, solute washout due to osmotic diuresis is not likely. UVNa did not increase (with the exception of a slight transitory increase on day 4 in the presence of colchicine) and this indicates that no major depression of sodium reabsorption (such as occurs after administration of 0.84±0.07 (7) 0.54±0.09 (7) 2.2540.206 (7) Preincubated with colchicine 0.21±0.02 (6) 0.78±0.03 (6) 0.46±0.04 (6) 2.16±0.65 (6) Preincubated with vinblastine 0.2140.02 (6) 0.79±0.07 (6) 0.44±0.07 (6) 2.2140.22 (6) Preincubation conditions as in Table IV . Activities of enzymes incubated with alkaloids were not significantly different (P > 0.05) from controls when evaluated by t test for paired observations. * Mean ±i:SEM; number of experiments in parentheses. saluretics) occurred. There was no significant increase in urinary potassium due to administration of colchicine and vinblastine, and excessive gastrointestinal loss of potassium is unlikely since no diarrhea was observed. Also in control experiments, no decrease in serum potassium was observed. These results suggest that the observed unresponsiveness to exogenous vasopressin is not caused by depletion of potassium (23) . A large alteration in glomerular filtration rate (GFR) could produce changes in urine flow and urine concentration. Total creatinine excretion did not change markedly in the course of experiments in either control animals or animals treated with alkaloids, and this observation, in conjunction with finding of normal plasma levels of creatinine at the end of the experiment, indicates that GFR did not change due to the action of drugs or hormone (Tables I and III ).-It is unlikely that the alkaloids damaged the renal tubules since the excretion of sodium, potassium, and creatinine was unaffected and no glucosuriaor proteinuria was detected. Hypercalcemia can inhibit the response to vasopressin (24) . In our control experiment, no changes in serum calcium were observed in colchicine-treated rats; Henneman, Montierth, and Nichols reported that colchicine caused hypocalcemia in rats (13) . Thus, hypercalcemia is an unlikely explanation for the unresponsiveness to exogenous vasopressin in rats treated with the alkaloids.
The view that colchicine and vinblastine blocked the effect of exogenous vasopressin by interfering with its cellular-action on the distal nephron finds further support in reported observations on the toad bladder (6) . In that system the tested alkaloids blocked the effect of (10) . In the present studies colchicine inhibited the antidiuretic response to exogenous vasopressin while lumicolchicine had no effect. Since only colchicine and not lumicolchicine can interact with microtubular protein both in vivo and in vitro (22) , the vasopressin-blocking effect of colchicine is probably related to its interaction with microtubular protein rather than to its direct effect on membranes in renal cells.
The inhibition of antidiuretic action of vasopressin was not complete, since urine osmolality remained always above osmolality of plasma. This feature also is similar to the findings in toad bladder (6) . Although the alkaloids clearly prevented the response to exogenous vasopressin, they apparently did not reverse the effect of endogenous vasopressin under our experimental conditions (urine osmolality on day 3 remained higher than serum osmolality; Tables I and III) . A possible explanation for this finding may be related-to the mechanism by which these alkaloids interfere with microtubules in this tissue. Microtubule-disrupting effects of colchicine and vinblastine may be due to their ability to prevent polymerization of microtubular subunits. Several studies indicate that monomers and polymers of microtubular protein exist in the cell in dynamic equilibrium (8) . It has been demonstrated that these alkaloids bind to the microtubular protein subunit (8), but do not interact with polymerized microtubules (25, 26) . In addition, colchicine prevents the polymerization of microtubular protein (27, 28) . If the cellular action of vasopressin promotes polymerization of microtubular protein, colchicine and vinblastine may prevent the action of vasopressin by binding to microtubular protein, thereby interfering with microtubule formation. On the other hand, under our experimental conditions the alkaloids may not have interacted with existing polymerized microtubules, and hence could not reverse the effect of endogenous vasopressin. Since microtubule-disrupting alkaloids inhibited the response to both exogenous vasopressin and cyclic AMP in the isolated toad bladder, the authors concluded that the alkaloids acted on a site distal to cyclic AMP generation (6) . Renal response to exogenous cyclic AMP is difficult to evaluate in the whole organism because exogenous cyclic AMP or its derivatives could possibly mimic not only the action of vasopressin on distal tubules but also of a host of other hormones, all mediated by cyclic AMP. Administration of cyclic AMP or its derivatives to the whole organism produced various effects, and findings varied from antidiuresis to no response to a clearly diuretic response (29) (30) (31) (32) .
In view of this, and also because colchicine and especially vinblastine were reported to influence enzymes of cyclic AMP metabolism from organs other than the kidney (33), we tested the effects of these two drugs on the adenylate cyclase and cyclic AMP phosphodiesterase from renal medulla in vitro. The known components of the cellular action of vasopressin are qualitatively similar in all mammalian renal medulla examined (15) , and bovine renal medulla was chosen for our in vitro studies because it was available in sufficient quantities for subcellular preparations.
Lack of inhibition of renal medullary adenylate cyclase and cyclic AMP phosphodiesterase (Table IV) (8, 34, 35) . In bovine renal medulla, the protein kinase activity' as well as the colchicine-binding protein (Fig. 4) (36) . Therefore, the possibility still remains that colchicine and vinblastine might act on some specific protein kinase that represents a very small fraction of the total protein kinase activity in the crude cytosol or that the inhibition is apparent only if the enzyme acts on a natural protein substrate that has not yet been identified. The ultimate site of vasopressin action appears to be the change of water permeability of lumenal plasma membranes (37) . According to some reports, appreciable amounts of microtubular protein were found to be tightly associated with cellular membranes (38, 39) . In renal medulla, microtubular protein, estimated by ['H]colchicine binding (14, 40) , was found almost exclusively in cytosol (Fig. 4) , a finding similar to that described for the tissue culture cells (40) . No major portion of colchicine-binding protein was found to be tightly associated with plasma membranes or other membrane particles in our in vitro system. The minimal amount of colchicinebinding activity detected in plasma membranes (less than 4% of the activity in cytosol) may well be a contamination by cytosolic proteins. Nevertheless, we do not exclude the possibility, suggested by the morphological findings in other cell systems (41) , that cytoplasmic microtubules may be in contact and act on the plasma membrane in the intact cells.
The role of cytoplasmic microtubules in the cyclic AMP action to increase water permeability is rather a matter of speculation at the present time. Two major possibilities may be considered. First, cyclic AMP may act directly or indirectly (e.g. via phosphorylation) to change some properties of microtubules (e.g. ability to assemble or turnover rate). Such cyclic AMP-induced change in microtubules may influence the lumenal plasma membrane permeability, e.g. by release of secretion granules (6, 8) or by direct change of topographic distribution of membrane proteins (42) . The degree of polymerization of microtubules in a submembranal layer of cytoplasm might also conceivably be associated with changes of water permeability and some mechanical properties of lumenal plasma membrane, elicited by vasopressin and cyclic AMP (43) .
An alternative possibility is that cyclic AMP does not interact with microtubules at all, but that the function of microtubules in cyclic AMP action is rather a passive or permissive one. Cytoplasmic microtubules may serve as structural elements that hold cyclic AMP-de-pendent enzymes (e.g. cyclic AMP-dependent protein kinase or protein phosphatase) acting on membranes in proper localization with their respective substrates (the membrane proteins). Microtubules may also provide a structural basis for compartmentalization of pools of substrates and modulators such as cyclic AMP, ATP, Ca, or Mg within the cell. In the latter situation, microtubuledissociating alkaloids may not interact and interfere with any of the individual components of cyclic AMP-mediated system (enzymes, membranes), but by disrupting the microtubular framework, they can render this system inoperative in the intact cells.
